In the last trading session, 1.81 million BioNTech SE ADR (NASDAQ:BNTX) shares changed hands as the company’s beta touched 1.28. With the company’s per share price at $101.72 changed hands at $3.92 or 4.01% during last session, the market valuation stood at $24.45B. BNTX’s last price was a discount, traded about -29.27% off its 52-week high of $131.49. The share price had its 52-week low at $76.53, which suggests the last value was 24.76% up since then.
Analysts gave the BioNTech SE ADR (BNTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 2 out of 13 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended BNTX as a Hold, 9 felt it is a Buy and 0 rated the stock as Underweight.
BioNTech SE ADR (NASDAQ:BNTX) trade information
Instantly BNTX was in green as seen at the end of in last trading. With action 7.64%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -10.73%, with the 5-day performance at 7.64% in the green. However, in the 30-day time frame, BioNTech SE ADR (NASDAQ:BNTX) is -0.09% down.
The consensus price target for the stock as assigned by Wall Street analysts is 134, meaning bulls need an upside of 24.09% from its current market value. According to analyst projections, BNTX’s forecast low is 134 with 134 as the target high. To hit the forecast high, the stock’s price needs a -31.73% plunge from its current level, while the stock would need to soar -31.73% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -25.87%. The 2025 estimates are for BioNTech SE ADR earnings to decrease by -98.67%, but the outlook for the next 5-year period is at -20.60% per year.
BNTX Dividends
BioNTech SE ADR is expected to release its next quarterly earnings report in June.
PRIMECAP MANAGEMENT CO/CA/ holds the second largest percentage of outstanding shares, with 1.9922% or 4.79 million shares worth $384.89 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund and iShares Trust-iShares Biotechnology ETF . With 2.27 shares estimated at $231.0 million under it, the former controlled 0.94% of total outstanding shares. On the other hand, iShares Trust-iShares Biotechnology ETF held about 0.43% of the shares, roughly 1.04 shares worth around $106.0 million.
